Related Experiment Video
Updated: Jan 21, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
CHA2DS2VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation
Giulia Renda1, Fabrizio Ricci2,3,4, Giuseppe Patti5
1Institute of Cardiology, Department of Neuroscience, Imaging and Clinical Sciences, and Center of Excellence on Aging, CeSI-Met, G. d'Annunzio University, Chieti-Pescara, Italy.
Insights
The CHA2DS2VASc score effectively predicts thromboembolic events and mortality in individuals with and without atrial fibrillation. Higher scores indicate increased risk for stroke, cardiovascular events, and death, aiding in risk stratification.
Area of Science:
- Cardiology
- Epidemiology
- Preventive Medicine
Background:
- The CHA2DS2VASc score is standard for assessing thromboembolic risk in non-valvular atrial fibrillation.
- Its utility in predicting outcomes in individuals without atrial fibrillation is less understood.
Purpose of the Study:
- To evaluate the prognostic value of the CHA2DS2VASc score for new-onset atrial fibrillation.
- To assess cardiovascular morbidity and mortality risks associated with the CHA2DS2VASc score in a general population.
Main Methods:
- Analysis of a population-based cohort (n=22,179) with and without atrial fibrillation history.
- Stratification into CHA2DS2VASc score groups (0-1-2-3-≥4) to compare major adverse cerebro-cardiovascular events and mortality.
- Assessment of annual atrial fibrillation incidence across CHA2DS2VASc strata.
Main Results:
- CHA2DS2VASc score ≥4 in non-atrial fibrillation patients showed stroke risk similar to atrial fibrillation patients with CHA2DS2VASc 2.
- The score demonstrated higher predictive accuracy for ischemic stroke in the non-atrial fibrillation group (AUC 0.60 vs. 0.56).
- CHA2DS2VASc ≥2 independently predicted all-cause death, cardiovascular death, ischemic stroke, and coronary events. Annual AF incidence exceeded 2% for CHA2DS2VASc ≥4.
Conclusions:
- The CHA2DS2VASc score is a valuable tool for predicting new-onset atrial fibrillation.
- It also effectively predicts adverse cardiovascular outcomes in both atrial fibrillation and non-atrial fibrillation populations.
- This score aids in comprehensive risk assessment across diverse patient groups.
Aims:
The CHA2DS2VASc score is used to evaluate the risk of thromboembolic events in patients with non-valvular atrial fibrillation. We assessed the prognostic yield of CHA2DS2VASc for new-onset atrial fibrillation, cardiovascular morbidity and mortality in a non-atrial fibrillation population.
Methods:
We analysed a population-based cohort of 22,179 middle-aged individuals with (n = 3542) and without (n = 18,367) a history of atrial fibrillation; we grouped the population into five CHA2DS2VASc strata (0-1-2-3-≥4), and compared the risk of major adverse cerebro-cardiovascular events and mortality. Furthermore, we analysed the annual incidence of atrial fibrillation across different CHA2DS2VASc strata.
Results:
Over a median follow-up of 15 years, 1572 patients (6.9%) had ischaemic strokes, 2162 (9.5%) coronary events and 5899 (26%) died. The cumulative incidence of ischaemic stroke in CHA2DS2VASc ≥ 4 subjects without atrial fibrillation was similar to patients with atrial fibrillation and CHA2DS2VASc 2, with a 10-year crude incidence rate of 0.91 (95% confidence interval (CI) 0.68-1.19) and 1.13 (95% CI 0.93-1.36) ischaemic strokes per 100 patient-years, respectively. CHA2DS2VASc in a non-atrial fibrillation population showed higher predictive accuracy for ischaemic stroke compared with an atrial fibrillation population (area under the curve 0.60 vs. 0.56; P = 0.001). In multivariable Cox regression analysis, CHA2DS2VASc ≥ 2 was an independent predictor of all-cause death (adjusted hazard ratio (aHR) 2.58; 95% CI 2.42-2.76), cardiovascular death (aHR 3.40; 95% CI 2.98-3.89), ischaemic stroke (aHR 2.20; 95% CI 1.92-2.53) and coronary events (aHR 1.83; 95% CI 1.63-2.04). The cumulative incidence of atrial fibrillation was greater with increasing CHA2DS2VASc strata, with an absolute annual incidence of more than 2% per year if CHA2DS2VASc ≥ 4.
Conclusion:
The CHA2DS2VASc score is a sensitive tool for predicting new-onset atrial fibrillation and adverse outcomes in subjects both with and without atrial fibrillation.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Introduction to z Scores
z scores...
Introduction to z Scores
z scores...
z Scores and Area Under the Curve
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...

